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Background: Germline mutations in the succinate dehydrogenase B (SDHB) gene predispose to hered-
itary paraganglioma (PGL) syndrome type 4. The aim of this study was to evaluate the clinical charac-
teristics and outcome of treatment strategies for patients with head and neck paraganglioma (HNPGL)
carrying SDHB germline mutations.
Methods: This was a retrospective evaluation of patients with HNPGL carrying SDHB germline muta-
tions in the Netherlands.
Results: In a Dutch nationwide cohort study of SDHB germline mutation carriers, 54 patients with a
total of 62 HNPGLs were identified. Forty-one of 54 patients (76 per cent) visited the outpatient clinic
because of associated complaints. Eight patients (15 per cent) had multiple PGLs. One patient (2 per
cent) developed a phaeochromocytoma and three (6 per cent) developed a malignant PGL. Twenty-seven
patients (50 per cent) had an operation for their HNPGL and 15 (28 per cent) received radiotherapy.
Three patients with HNPGL (6 per cent) were diagnosed with additional non-paraganglionic tumours.
Conclusion: If an SDHB germline mutation is identified in a patient with HNPGL, the clinician should
be aware of the variable manifestations of the SDHB-linked tumour syndrome, the risk of catecholamine
excess, concurrent phaeochromocytoma, and association with non-paraganglionic tumours.
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Introduction
Paragangliomas (PGLs) of the head and neck are predom-
inantly benign hypervascular tumours that arise from neu-
ral crest cells of the autonomic nervous system. Head and
neck paragangliomas (HNPGLs) most frequently origi-
nate from the paraganglia in the bifurcation of the carotid
artery, the jugular foramen, along the vagus nerve or along
the tympanic nerve1. Other locations are the nasal cav-
ity, paranasal sinuses, parotid gland, cervical sympathetic
chain, pharynx, larynx, trachea, aortic arch, ciliary gan-
glion and thyroid gland2. HNPGLs are associated with
extra-adrenal PGLs arising in the thorax and abdomen,
predominantly along the sympathetic trunk, and with
phaeochromocytomas of the adrenal gland.
These extra-adrenal PGLs and phaeochromocytomas
usually present with signs and symptoms of catecholamine
excess3. Generally HNPGLs are parasympathetic in ori-
gin, and symptoms depend on the localization, tumour size,
compression of surrounding structures and associated cra-
nial nerve deficits. Between 4 and 30 per cent of HNPGLs
secrete catecholamines4,5. HNPGLs can occur sponta-
neously or as part of a hereditary syndrome. A rapidly
expanding number of genes are associated with hereditary
PGL.Hereditary PGL syndrome is causedmost frequently
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Table 1 Clinical characteristics of patients with SDHB-linked
head and neck paragangliomas
Negative
family history
(n=38)
Positive
family history
(n=16)
Age at diagnosis (years)* 47 (12–77) 44 (28–83)
Sex ratio (M : F) 19 : 19 7 : 9
Malignant paraganglioma 3 0
Multiple head and neck paragangliomas 6 1
Phaeochromocytoma 1 0
Extra-adrenal paraganglioma 0 0
Carotid body tumour 11 11
Jugular body tumour 13 1
Vagal body tumour 8 4
Tympanic body tumour 9 1
*Values are mean (range).
by genes encoding succinate dehydrogenase (SDH) sub-
units or co-factors (SDHA/B/C/D/AF2 genes). Other asso-
ciated genes are RET , NF1, VHL, HIF2A, FH, TMEM127
and MAX6,7. In the Netherlands, mutations in SDHD,
SDHB and SDHAF2 are responsible for most hereditary
cases. SDHD-related PGLs are usually characterized by
multiple PGLs located predominantly in the head and
neck region, with a low frequency of malignancy. In con-
trast, SDHB mutation carriers are reported to develop
single PGLs and metastatic PGLs more frequently8–12.
Recently it has become clear that the SDHB-linked tumour
syndrome not only comprises PGLs and phaeochromo-
cytomas, but also non-paraganglionic tumours such as
renal clear cell carcinoma, gastrointestinal stromal tumours
(GISTs) and pituitary tumours6–12.
In a recently published nationwide evaluation of 194
SDHB mutation carriers13, 54 patients (27.8 per cent)
were identified with SDHB-linked HNPGLs. In the
present study, the clinical characteristics and clini-
cal course, treatment modalities and outcome of these
patients with HNPGL linked to SDHB mutations were
evaluated.
Methods
Patients with HNPGL were identified in a Dutch nation-
wide cohort of SDHB germline mutation carriers. The
genotype and phenotype of this nationwide cohort have
been described elsewhere13. SDHB mutation carriers and
patients with PGL were investigated in multiple centres
according to structured protocols used for standard care of
PGL in the Netherlands14,15. Carriers were offered annual
clinical surveillance for concurrent HNPGL, concurrent
phaeochromocytomas and extra-adrenal PGLs in depart-
ments of otorhinolaryngology and endocrinology. For
Table 2 Details of SDHB germline mutations in patients with a
head and neck paraganglioma
cDNA mutation Protein alteration No. of patients
Exon 3 deletion† p.? 18
c.423+1G>A† p.? 11
c.653G>C p.(Trp218Ser) 3
c.137G>A p.(Arg46Gln) 3
c.200+1G>A p.? 2
c.328A>C p.(Thr110Pro) 2
c.686_725del p.(Glu229fs) 1
c.725G>A p.(Arg242His) 1
c.761C>T p.(pro254Leu) 1
Exon 1 deletion p.? 1
Promoter to exon 8 deletion p.0 1
Promoter and exon 1 deletion p.? 1
c.119A>C p.(Lys40Thr) 1
c.649C>T p.(Arg217Cys) 1
c.1A>G p.? 1
c.590C>G p.(Pro197Arg) 1
c.292T>C p.(Cys98Arg) 1
c.654G>A p.(Trp218†) 1
c.380T>C p.(Ile127Thr) 1
c.418G>T p.(Val140Phe) 1
c.574T>C p.(Cys192Arg) 1
†Dutch founder mutations.
SDHB mutation carriers over 18 years of age, surveillance
consisted of MRI of the head and neck region once every
3 years, and MRI or CT of the thorax, abdomen and pelvis
once every 2–3 years. At the time of this study there were
no national structured protocols for surveillance of SDHB
mutation carriers aged less than 18 years. Therefore, the
method and interval of surveillance in this age category var-
ied between centres.
When HNPGL was diagnosed, treatment or intensi-
fied periodic examination was offered, guided by tumour
characteristics such as location, size (defined as the largest
diameter of the HNPGL on imaging), growth rate,
associated symptoms, and patient characteristics such
as age, general condition and co-morbidity, according
to local protocols. A wait and scan policy, radiotherapy,
surgical resection, or combinations thereof, were possi-
ble treatment strategies. Annual biochemical screening
included the measurement of adrenaline (epinephrine),
noradrenaline (norepinephrine), vanillylmandelic acid
(VMA), dopamine (D), metanephrine, normetanephrine
and/or 3-methoxytyramine (3-MT) in two 24-h urinary
samples, and/or plasma free (nor)metanephrine and/or
3-MT. In case of excessive catecholamine secretion (any
value above the upper reference limit), radiological assess-
ment by MRI or CT of the thorax, abdomen and pelvis
and/or [123I]metaiodobenzylguanidine (MIBG)scan/PET
with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG
PET)/18F-L-dihydroxyphenylalanine (18F-DOPA) PET
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Fig. 1 Presenting symptoms in patients with SDHB-linked head and neck paraganglioma (HNPGL). The proportion of patients with
HNPGL who presented with a specific symptom is shown per tumour site. Some patients did not have any symptoms, and the
HNPGL was identified coincidentally (as an incidentaloma) or through presymptomatic screening. The single paraganglioma that was
diagnosed in the tonsil is not shown. a Carotid, b jugular, c vagal, d tympanic
was performed to identify potential sources of excessive
catecholamine production outside the head and neck
region. As no histological features of the primary tumour
reliably distinguish benign from malignant (HN)PGLs,
malignant disease was defined as the presence of metastases
(paraganglionic cells in non-neuroendocrine tissue distant
from the primary tumour).
After obtained informed consent, clinical, radiological
and genetic data of patients with HNPGL were collected.
Duration of the follow-up was defined as the time from the
date of first presentation to the most recent outpatient visit
within the study interval.
The study was approved by the medical ethics committee
of Leiden University Medical Centre (number P13.161);
participating centres complied with their local medical
ethics committee requirements.
SPSS® version 20.0 (IBM, Armonk,NewYork, USA) was
used for data analysis.
Results
Clinical status
In all, 54 patients, 28 female (52 per cent) and 26 male
(48 per cent), with a total of 62 HNPGLs were identified
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 62–69
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Table 3 Clinical characteristics, treatment strategies and outcome of patients with multiple SDHB-linked head and neck paragangliomas
Treatment
Sex SDHB mutation Presenting symptoms Tumour and location
Age at
diagnosis
(years) Strategy
Tumour
treated
Age
(years) Outcome
Follow-up
(years)
F c.653G>C Unknown VBTL, PHEO 19 Surgery PHEO 19 AWD 37
F Exon 3 deletion Hearing loss, pulsatile
tinnitus, swelling neck,
hoarseness
CBTR, JBTR, JBTL 30 RT JBTL 30 AWD 2
M c.761C>T Swelling neck CBTL, JBTR 33 Surgery CBTL 33 AWD 28
M c.423+1G>A None (PST) VBTR, JBTL 49 RT JBTL 56 AWD 6
F Exon 3 deletion Pulsatile tinnitus VBTR, JBTL 49 Surgery JBTL 49 AWD 15
VBTR 50
RT JBTL 65
M Exon 3 deletion Pulsatile tinnitus VBTL, TBTR 52 RT TBTR 52 AWD 2
F c.649C>T Swelling neck CBTR, CBTL 55 Surgery CBTL 55 AWD 14
M c.590C>G None (incidentaloma) CBTR, CBTL 56 Watchful waiting AWD 10
VBTL, vagal body tumour left; PHEO, phaeochromocytoma; AWD, alive with disease; CBTR, carotid body tumour right; JBTR, jugular body tumour
right; JBTL, jugular body tumour left; RT, radiotherapy; CBTL, carotid body tumour left; PST, presymptomatic screening; VBTR, vagal body tumour
right; TBTR, tympanic body tumour right.
Table 4 Clinical characteristics, treatment strategies and outcome of patients with malignant SDHB-linked head and neck
paragangliomas
Sex
SDHB
mutation
Age
(years)*
Age
(years)†Location
Size of
primary
tumour at initial
diagnosis (mm)
Location of
metastases
Catecholamine
excess at
diagnosis
Treatment of
primary tumour
Treatment of
metastases Outcome
F c.418G>T 18 20 Right
tonsil
20 Lymph nodes,
bone (vertebra)
Urinary level raised
(3-MT); plasma
normal
Surgery Surgery and
RT
AWD at age 22
years;
subsequently
lost to follow-up
M c.423+1G>A 48 57 JBTL Unknown Bone (vertebra) Urinary level raised
(VMA, D, A, NA);
plasma not
measured
Surgery and RT
(at age 57 years)
None Died from disease
at age 57 years
F Exon 3
deletion
35 66 CBTL 48 Lymph nodes,
bone
Urine negative;
plasma not
measured
Surgery and RT
(at age 66 years)
(recurrent CBTL)
None AWD at age 66
years
*Age at diagnosis of head and neck paraganglioma; †age at diagnosis of metastatic disease. 3-MT, 3-methoxytyramine; RT, radiotherapy; AWD, alive with
disease; JBTL, jugular body tumour left; VMA, vanillylmandelic acid; D, dopamine; A, adrenaline (epinephrine); NA, noradrenaline (norepinephrine);
CBTL, carotid body tumour left.
in a nationwide evaluation of SDHB mutation carriers13.
The mean age of diagnosis was 45⋅9 (range 11–77) years.
Sixteen patients (30 per cent) had a positive family history,
and 38 (70 per cent) presented with a negative family
history (Table 1). The mean duration of follow-up was 7⋅8
(median 4⋅5, range 0⋅1–36⋅9) years.
Genetics
In all, 21 different SDHB germline mutations were identi-
fied (Table 2). The most prevalent SDHB germline muta-
tions are known as Dutch founder mutations – a deletion
of exon 3 (18 patients, 33 per cent) and the c.423+1G>A
mutation (11 patients, 20 per cent).
Presenting symptoms
Thirteen patients (24 per cent) had no associated signs or
symptoms at the time of diagnosis, and the tumour was
identified as a result of presymptomatic screening of known
SDHB mutation carriers (11 patients) or as an inciden-
taloma (2). Forty-one patients (76 per cent) with HNPGL
came tomedical attention as a result ofHNPGL-associated
signs or symptoms. The occurrence and type of presenting
symptoms depended on the location of the tumour in the
head and neck region (Fig. 1).
The majority of patients with tympanic and jugulotym-
panic PGLs presented with symptoms or signs (20 of 24,
83 per cent), mostly hearing loss and pulsatile tinnitus,
whereas the majority with a vagal body PGL (8 of 12,
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 62–69
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Table 5 Overall outcome and treatment strategy in patients with a solitary SDHB-linked head and neck paraganglioma
Treatment Outcome
Tumour location Overall outcome Mean follow-up (years) Strategy n NED AWD DFD LTF
Carotid body tumour (n = 18) NED 9 7⋅8 Watchful waiting 6 – 6 – –
AWD 7 Surgery 11 9 – – 2
DFD 0 RT – – – – –
LTF 2 Surgery + adjuvant RT 1 – 1 – –
Jugular body tumour (n = 10) NED 0 7⋅6 Watchful waiting 4 – 3 – 1
AWD 8 Surgery 1 – 1 – –
DFD 1 RT 1 – 1 – –
LTF 1 Surgery + adjuvant RT 4 – 3 1 –
Tympanic body tumour (n = 9) NED 6 8⋅2 Watchful waiting 2 – 2 – –
AWD 3 Surgery 4 4 – – –
DFD 0 RT 2 – 2 – –
LTF 0 Surgery + adjuvant RT 1 1 – – –
Vagal body tumour (n = 8) NED 0 5⋅9 Watchful waiting 6 – 5 – 1
AWD 7 Surgery 1 – 1 – –
DFD 0 RT 1 – 1 – –
LTF 1 Surgery + adjuvant RT – – – – –
NED, no evidence of disease; AWD, alive with disease; DFD, died from disease; LTF, lost to follow-up; RT, radiotherapy.
67 per cent) had no symptoms at the time of diagnosis.
Cranial nerve deficit (causing hoarseness, dysphagia and
hypoglossal palsy) was most commonly seen in jugular
PGLs. Seven carotid body tumours were asymptomatic and
the tumour was identified coincidentally (as an inciden-
taloma) or through presymptomatic testing (7 of 24, 29 per
cent). Nineteen SDHB carriers with anHNPGL presented
with hypertension (19 of 54, 35 per cent).
Multicentricity and non-paraganglionic tumours
Multiple PGLs were present in eight (15 per cent) of
the 54 patients with HNPGL to a maximum of three
concurrent tumours (Table 3). In five patients, multiple
HNPGLs were discovered during initial imaging. Two
patients were initially diagnosed with a solitary HNPGL
and developed a second, metachronous, HNPGL dur-
ing follow-up. One patient (2 per cent) underwent an
adrenalectomy because of a phaeochromocytoma 36 years
before the diagnosis of a vagal body PGL. No concurrent
extra-adrenal PGLs were identified in this SDHB-linked
HNPGL patient cohort. Three patients (6 per cent) were
diagnosed with non-paraganglionic tumours additional
to their HNPGL: a melanoma, a pituitary microprolacti-
noma and low-grade B-cell non-Hodgkin lymphoma.
Although multiple non-paraganglionic tumours have
been shown to be part of the SDHB-linked tumour spec-
trum, SDHB immunostaining was not performed on the
non-paraganglionic tumours found in this study, and so
no definitive causal relation with the SDHB germline
mutation could be established16.
Location and size
Themost frequently found paraganglioma locations within
the head and neck region were the jugular foramen (25
tumours: 14 left, 11 right), the carotid bifurcation (24
tumours: 13 left, 11 right) and along the vagal nerve (12
tumours: 6 left, 6 right) (Table 1). One patient had a PGL
in the right tonsil. Of 24 patients with a jugulotympanic
tumour, ten had an isolated tympanic tumour (Fisch type
A or B17). One of the ten patients with a tympanic PGL
had a concurrent carotid body HNPGL.
Mean tumour size at first presentation differed depend-
ing on the location of the tumour; the mean size on initial
imaging of vagal PGL was 35 (range 4–70) mm, followed
by carotid body PGL (28 (4–58) mm), jugular PGL (26
(17–44) mm) and tympanic PGL (10 (4–22) mm).
Malignancy
Three patients with HNPGL (6 per cent) developed
metastatic disease (Tables 1 and 4). Initially, these three
patients had solitary, seemingly benign, HNPGLs. They
developed metastases during follow-up at 2⋅2, 9⋅2 and 31⋅3
years after initial diagnosis. No clear associations between
the occurrence of metastatic disease and genetic factors
such as SDHBmutation type, or clinical factors such as age
of the patient, size of the initial tumour or location of the
initial tumour, were found (Table 4).
Catecholamine excess
Screening for catecholamine excess was performed at the
time of diagnosis and at annual intervals during follow-up
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 62–69
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by urine and/or plasma analysis in 52 of the 54 patients.
In all, 27 (52 per cent) of these 52 patients tested positive
for catecholamine excess during follow-up. At the time
of diagnosis, 14 patients tested positive for adrenaline
(epinephrine), noradrenaline (norepinephrine) or their
metabolites, and seven tested positive for dopamine or
its metabolite. The results of catecholamine screening in
the three patients with metastatic HNPGL is outlined in
Table 4.
Treatment strategy and outcome
Twenty-seven patients (50 per cent) had an operation and
15 (28 per cent) received radiotherapy, either as single
modality or as adjuvant therapy. In 19 patients (35 per
cent) no intervention was performed. Treatment strategies
and outcome for patients with a solitary HNPGL are out-
lined in Table 5. Nine of 11 patients with a solitary carotid
body tumour showed no evidence of disease after surgery;
the other two patients were lost to follow-up. Of five
patients with a solitary jugular body tumour who under-
went surgery, four received adjuvant radiotherapy although
tumour-free margins were never achieved at resection.
Only two of eight patients with a vagal body PGL received
a form of treatment (1 radiotherapy and 1 surgery), and
seven of these patients were alive with disease at the end
of follow-up.
Discussion
This study describes patients withHNPGL identified from
a nationwide cohort of SDHBmutation carriers. The mean
age at diagnosis of an HNPGL in this cohort (45⋅9 years)
was higher than that reported previously, of between 30
and 37 years8,10,18. In the Netherlands, tumour screening
in SDHB-linked families is advised from the age of 18 years
onwards. A later start for tumour screening has been pro-
posed based on statistical models of the age-dependent
penetrance of SDHB mutations and, although the mean
age in this cohort was relatively high, the youngest patient
developed an HNPGL at age 11 years, and an 18-year-old
patient had already developed PGL metastases. The opti-
mal age to start screening for PGLs in SDHB mutation
carriers thus remains a subject of debate19–21.
The majority of patients in this cohort carried a Dutch
SDHB founder mutation, either a deletion of exon 3 (18
of 54 patients) or the c.423+1G>A mutation (11 patients).
Interestingly, themajority of patients with an SDHB-linked
HNPGL reported a negative family history (70 per cent),
probably reflecting the low penetrance of SDHB-linked
PGL syndrome22,23. In addition, patients and their physi-
cians may have been unaware that phaeochromocytomas
and some non-paraganglionic tumours such asGISTs, pitu-
itary tumours and renal clear cell carcinomas are part of the
tumour spectrum caused by SDHB germline mutations13.
Patients with SDHB-linked HNPGL had a low risk (8 of
54, 15 per cent) of developingmultiple PGLs, in contrast to
the risk for SDHDmutation carriers (60–79 per cent)9,10,24.
Only a single patient in this SDHB-linked HNPGL cohort
developed a phaeochromocytoma. Thirty-five years after
an adrenalectomy for this tumour, this patient developed
a vagal body tumour. No patient with an HNPGL devel-
oped extra-adrenal PGLs, even though these tumours are
reported to be relatively prevalent in SDHB mutation
carriers12.
The risk of malignancy in this cohort was also lower
than expected, with only three patients (6 per cent) devel-
oping metastases. All three presented with an apparently
benign solitaryHNPGL (located in the tonsil, jugular body
and carotid body). Metastatic disease developed during
follow-up, at varying time intervals from initial HNPGL
diagnosis (range 2⋅2–31⋅3 years). No clear clinical or
genetic indicators of malignancy were identified.
Most patients with a carotid, jugular or tympanic body
HNPGL had one or more complaints associated with
the tumour (Fig. 1). Of the 13 patients (24 per cent)
without symptoms, vagal body tumours dominated (over
50 per cent). The benefit of detecting asymptomatic,
slow-growing benign PGLs through presymptomatic
screening of SDHB mutation carriers is uncertain, as
intervention by either surgery or radiotherapy may
cause more morbidity than the tumour itself. Con-
versely, early diagnosis seems favourable in growing
tumours, catecholamine-producing tumours and malig-
nant tumours, allowing for timely therapeutic intervention.
As the occurrence or type of symptoms does not reliably
predict tumour growth, catecholamine excess or malig-
nancy, adequate surveillance of SDHB germline mutation
carriers is mandatory and should include screening for
catecholamines or their metabolites, along with periodic
radiological investigation of the abdomen, the pelvic
region, thorax, and head and neck region. In patients
with SDHB-linked HNPGLs, these regions should be
evaluated not only for the occurrence of concurrent PGLs
and phaeochromocytomas, but also for SDHB-associated
non-paraganglionic tumours and PGL metastases.
The choice of an optimal treatment strategy for
HNPGLs is complex and depends on diverse factors
such as the causal gene mutation, patient character-
istics (age, condition and preferences) and HNPGL
characteristics (localization, size and growth rate, cate-
cholamine excess and associated cranial nerve deficits).
Opinions regarding adequate management of HNPGLs
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have changed over time and vary from centre to centre.
Symptoms and risks conferred by the tumour should
be weighed against the morbidity of the treatment. As
the risk to SDHB-linked patients is not confined to one
specific anatomical region or tumour type, these decisions
are probably made most appropriately by a dedicated
multidisciplinary team.
Genetic counselling and DNA testing is recommended
for all patients with HNPGL, as different PGL-associated
genes confer different clinical risks and may warrant differ-
ent management strategies. If an SDHB germline mutation
is identified in a patient with HNPGL, the clinician should
be aware of the variable manifestations of the SDHB-linked
tumour syndrome and, irrespective of the chosen manage-
ment strategy, periodic surveillance should be performed
including screening for catecholamine excess, concur-
rent PGL or phaeochromocytoma, metastatic PGL and
SDHB-associated non-paraganglionic tumours.
Disclosure
The authors declare no conflict of interest.
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